Statements (54)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:vaccine
|
| gptkbp:availability |
widely available
|
| gptkbp:average_temperature |
2-8° C
|
| gptkbp:clinical_trial |
extensively studied
|
| gptkbp:community_health |
significantly reduced hepatitis B incidence
|
| gptkbp:contraindication |
severe allergic reaction to yeast
|
| gptkbp:defense |
included in EPI (Expanded Program on Immunization)
|
| gptkbp:development |
developed by recombinant DNA technology
|
| gptkbp:dosage_form |
3 doses
not routinely recommended |
| gptkbp:first_dose_timing |
at birth
|
| gptkbp:first_introduced |
gptkb:1981
|
| https://www.w3.org/2000/01/rdf-schema#label |
hepatitis B vaccine
|
| gptkbp:is_effective_against |
over 90% in healthy individuals
|
| gptkbp:is_recommended_for |
gptkb:children
infants adults at risk |
| gptkbp:is_vulnerable_to |
long-lasting immunity
subunit vaccine ongoing research for improved formulations high in many countries post-marketing surveillance conducted 0, 1, 6 months first vaccine against a viral infection ACIP recommends vaccination for high-risk adults CDC recommends vaccination for all infants administered in a series of injections available in low-income countries collaborations with WHO and UNICEF considered safe for pregnant women cost-effective intervention distributed globally through health organizations effective in preventing chronic infection prevention of liver cancer public health campaigns promote vaccination recommended for healthcare workers reduces transmission rates research into combination vaccines |
| gptkbp:regulatory_compliance |
approved by FDA
approved by EMA |
| gptkbp:route_of_administration |
intramuscular injection
|
| gptkbp:second_dose_timing |
1-2 months after first dose
|
| gptkbp:side_effect |
fatigue
fever mild pain at injection site rare serious adverse events |
| gptkbp:targets |
gptkb:virus
|
| gptkbp:third_dose_timing |
6-18 months after first dose
|
| gptkbp:trade_names |
gptkb:Recombivax_HB
gptkb:Engerix-B |
| gptkbp:type |
gptkb:recombinant_vaccine
|
| gptkbp:vaccine_production |
produced using yeast cells
|
| gptkbp:bfsParent |
gptkb:virus
|
| gptkbp:bfsLayer |
4
|